Posted by Michael Wonder on 16 Apr 2019
Concerns over single brand move for epilepsy sufferers
16 April 2019 - Epilepsy New Zealand is raising concerns about PHARMAC changing its funding to just a single brand of lamotrigine epilepsy medication.
About 12,500 people take some brand of lamotrigine, for either epilepsy or a mental health condition like bipolar.
From 1 May, everyone using Lamictal and Arrow-Lamotrigine brands of lamotrigine 25, 50 or 100 milligram dispersible tablets will need to transition to the Logem brand to keep accessing funding.
After a five-month transition period, Logem will be the only brand funded by PHARMAC.
